Belzupacap sarotalocan is a recombinant protein commercialized by Aura Biosciences, with a leading Phase III program in Uveal Melanoma. According to Globaldata, it is involved in 7 clinical trials, of which 1 was completed, 3 are ongoing, 2 are planned, and 1 was terminated. GlobalData uses proprietary data and analytics to provide a complete picture of Belzupacap sarotalocan’s valuation in its risk-adjusted NPV model (rNPV). Buy the model here.

Smarter leaders trust GlobalData

The revenue for Belzupacap sarotalocan is expected to reach an annual total of $85 mn by 2039 globally based off GlobalData’s Expiry Model. The drug’s revenue forecasts along with estimated costs are used to measure the value of an investment opportunity in that drug, otherwise known as net present value (NPV). Applying the drug’s phase transition success rate to remaining R&D costs and likelihood of approval (LoA) to sales related costs provides a risk-adjusted NPV model (rNPV). The rNPV model is a more conservative valuation measure that accounts for the risk of a drug in clinical development failing to progress.

Belzupacap sarotalocan Overview

AU-011 is under development for the treatment of ocular melanoma (uveal and choroidal melanoma), head and neck cancer squamous cell carcinoma, non muscle invasive bladder cancer (NMIBC) (superficial bladder cancer), muscle invasive bladder cancer (MIBC), cancers of the ocular surface and other HSPG expressing cancers. It is administered as an intravitreal, suprachoroidal, intratumoral and intramural route. The therapeutic candidate is developed based on Nanosmart technology. The drug candidate is a VDC (virus like drug conjugate).

Aura Biosciences Overview

Aura Biosciences is a clinical-stage biotechnology company that develop a new standard of care across multiple cancer indications and enables broad range of solid tumors using VLPs. The company is headquartered in Boston, Massachusetts, the US.
The operating loss of the company was US$85 million in FY2023, compared to an operating loss of US$60.3 million in FY2022. The net loss of the company was US$76.4 million in FY2023, compared to a net loss of US$58.8 million in FY2022.

For a complete picture of Belzupacap sarotalocan’s valuation, buy the drug’s risk-adjusted NPV model (rNPV) here.

This content was updated on 20 May 2024

Premium Insights


The gold standard of business intelligence.

Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.


GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

To create this model, GlobalData takes into account factors including patent law, known and projected regulatory approval processes, cash flows, drug margins and company expenses. Combining these data points with GlobalData’s world class analysis creates high value models that companies can use to help in evaluation processes for each drug or company.

The rNPV method integrates the probability of a drug reaching a clinical stage into the cash flow at that time, which provides a more accurate valuation, as it considers the probability that the drug never makes it through the clinical pathway to commercialization. GlobalData’s rNPV model uses proprietary likelihood of approval (LoA) and phase transition success rate (PTSR) data for the indication in the highest development stage, which can be found on GlobalData’s Pharmaceutical Intelligence Center.